Quick Answer
Orchestra BioMed Holdings, Inc. reported Operating Income of -$51.81 million for fiscal year 2025.
Orchestra BioMed Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$51.81M | +19.4% |
| 2024 | -$64.30M | -24.8% |
| 2023 | -$51.51M | -57.7% |
| 2022 | -$32.66M | -8172.7% |
| 2021 | -$394.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.31M | -24.3% | -5.1% |
| June 30, 2025 | -$19.33M | -14.6% | -2.1% |
| March 31, 2025 | -$18.92M | -31.2% | -15.8% |
| September 30, 2024 | -$16.34M | -12.5% | +3.1% |
| June 30, 2024 | -$16.86M | -30.1% | -16.9% |
| March 31, 2024 | -$14.42M | -24.9% | +0.7% |
| September 30, 2023 | -$14.52M | -44.3% | -12.1% |
| June 30, 2023 | -$12.96M | -69.7% | -12.2% |
- Orchestra BioMed Holdings, Inc. showed an increase of +19.4% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Orchestra BioMed Holdings, Inc.’s operating income has declined by 13023.8% (from -$394.8 thousand to -$51.81 million).
- The most recent figure is from Orchestra BioMed Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: